BIOGEN INC. - 26 Nov 2021 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role: 10%+ Owner
Signature: BIOGEN INC. By: /s/ Michael Dambach, Vice President and Treasurer
Issuer symbol: SGMO
Transactions as of: 26 Nov 2021
Net transactions value: -$248,434
Form type: 4
Filing time: 30 Nov 2021, 15:20:45 UTC
Next filing: 03 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SGMO	Common Stock	Sale	$248,434	-28,884	-0.12%	$8.60^*	24,391,273	26 Nov 2021	By Biogen MA Inc.	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.74, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2	Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.

Content

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.74, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.